Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.642
Peer-review started: April 30, 2020
First decision: May 15, 2020
Revised: May 18, 2020
Accepted: May 21, 2020
Article in press: May 21, 2020
Published online: June 15, 2020
Processing time: 45 Days and 20.7 Hours
Mucinous cystic neoplasm (MCN) of the pancreas is characterized by mucin-producing columnar epithelium and dense ovarian-type stroma and at risk for malignant transformation. Early diagnosis and treatment of MCN are particularly important.
To investigate the clinical characteristics of and management strategies for pancreatic mucinous cystadenoma (MCA) and mucinous cystadenocarcinoma (MCC).
The clinical and pathological data of 82 patients with pancreatic MCA and MCC who underwent surgical resection at our department between April 2015 and March 2019 were retrospectively analyzed.
Of the 82 patients included in this study, 70 had MCA and 12 had MCC. Tumor size of MCC was larger than that of MCA (P = 0.049). Age and serum levels of tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA12-5 were significantly higher in MCC than in MCA patients (P = 0.005, 0.026, and 0.037, respectively). MCA tumor size was positively correlated with serum CA19-9 levels (r = 0.389, P = 0.001). Compared with MCC, MCA had a higher minimally invasive surgery rate (P = 0.014). In the MCA group, the rate of major complications was 5.7% and that of clinically relevant pancreatic fistula was 8.6%; the corresponding rates in the MCC group were 16.7% and 16.7%, respectively.
Tumor size, age, and serum CEA, CA19-9, and CA12-5 levels may contribute to management of patients with MCN. Surgical resection is the primary treatment modality for MCC and MCA.
Core tips: In this study, we retrospectively analyzed the clinical and pathological records related with pancreatic mucinous cystadenoma (MCA) and mucinous cystadenocarcinoma (MCC). We found that the MCC tumor size was larger than that of MCA, and age, serum carcinoembryonic antigen, carbohydrate antigen (CA) 19-9, and CA12-5 levels were also higher in MCC patients. As the tumor size of MCA increased, the level of serum CA19-9 also increased. Surgical resection is the primary treatment for MCC and MCA.